Nomura Holdings’s Vir Biotechnology VIR Stock Holding History

Nomura Holdings’s Portfolio VIR Stock Details VIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$979K	Buy	96,100 +50,000	+108%	+$476K	﹤0.01%	1363
2026 Q1	$413K	Buy	+46,100	New	+$367K	﹤0.01%	1420
2025 Q4	–	Sell	-40,000	Closed	-$228K	–	2186
2025 Q3	$228K	Hold	40,000	–	–	﹤0.01%	1757
2025 Q2	$202K	Hold	40,000	–	–	﹤0.01%	1303
2025 Q1	$259K	Buy	+40,000	New	+$356K	﹤0.01%	1634

Other funds holding VIR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AVM

Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

GSK plc London $602M AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Nomura Holdings's VIR Position: Q2 2026 in Review

Nomura Holdings sold out of Vir Biotechnology (VIR) in Q2 2026, closing a stake of 50,040 shares — an estimated $476K sold.

Nomura Holdings first reported a position in VIR in Q2 2025 and held it in 3 quarters. The position peaked at $448K in Q1 2026. 237 funds tracked by Wall St. Rank hold VIR as of Q2 2026.

Nomura Holdings reported no remaining Vir Biotechnology position as of Q2 2026 after selling out during the quarter.
Nomura Holdings sold 50,040 Vir Biotechnology shares in Q2 2026, an estimated $476K.
Nomura Holdings first reported a position in Vir Biotechnology in Q2 2025 and held it in 3 quarters.
Nomura Holdings's Vir Biotechnology position peaked at $448K in Q1 2026.
237 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2026.

Based on Nomura Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.